vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $23.1M, roughly 1.6× Commercial Bancgroup, Inc.).
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
CBK vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $37.2M |
| Net Profit | $9.5M | — |
| Gross Margin | — | 30.8% |
| Operating Margin | — | -185.1% |
| Net Margin | 41.3% | — |
| Revenue YoY | — | -57.1% |
| Net Profit YoY | 9.7% | — |
| EPS (diluted) | $0.69 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | $37.2M | ||
| Q4 25 | $23.5M | $225.6M | ||
| Q3 25 | $22.8M | $150.9M | ||
| Q2 25 | — | $101.0M | ||
| Q1 25 | — | $86.7M | ||
| Q4 24 | — | $126.7M | ||
| Q3 24 | — | $115.2M | ||
| Q2 24 | — | $130.2M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $43.7M | ||
| Q3 25 | $9.5M | $21.6M | ||
| Q2 25 | — | $-9.4M | ||
| Q1 25 | — | $-18.8M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $-17.0M |
| Q1 26 | — | 30.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 72.6% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 76.7% | ||
| Q2 24 | — | 77.6% |
| Q1 26 | — | -185.1% | ||
| Q4 25 | — | 28.1% | ||
| Q3 25 | 53.8% | 13.7% | ||
| Q2 25 | — | -12.5% | ||
| Q1 25 | — | -30.9% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | -10.7% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | 19.4% | ||
| Q3 25 | 41.4% | 14.3% | ||
| Q2 25 | — | -9.3% | ||
| Q1 25 | — | -21.7% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | -13.1% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $0.31 | ||
| Q3 25 | $0.77 | $0.11 | ||
| Q2 25 | — | $-0.10 | ||
| Q1 25 | — | $-0.17 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $91.4M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $2.3B | $520.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $91.4M | ||
| Q4 25 | — | $93.7M | ||
| Q3 25 | $154.8M | $63.7M | ||
| Q2 25 | — | $73.1M | ||
| Q1 25 | — | $110.0M | ||
| Q4 24 | — | $135.6M | ||
| Q3 24 | — | $94.3M | ||
| Q2 24 | — | $89.9M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $300.1M | ||
| Q3 25 | $245.2M | $255.1M | ||
| Q2 25 | — | $233.2M | ||
| Q1 25 | — | $242.9M | ||
| Q4 24 | — | $262.9M | ||
| Q3 24 | — | $278.5M | ||
| Q2 24 | — | $263.5M |
| Q1 26 | $2.3B | $520.0M | ||
| Q4 25 | $2.3B | $598.7M | ||
| Q3 25 | $2.2B | $509.8M | ||
| Q2 25 | — | $461.1M | ||
| Q1 25 | — | $467.4M | ||
| Q4 24 | — | $497.9M | ||
| Q3 24 | — | $446.3M | ||
| Q2 24 | — | $443.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
ORGO
Segment breakdown not available.
